(202 days)
Not Found
No
The summary describes standard medical image processing and 3D modeling software functionalities. There is no mention of AI, ML, or related concepts in the intended use, device description, or performance studies.
No.
The device is described as a software interface and image segmentation system used for transferring medical imaging information, calculating 3D models, performing measurements, and treatment planning. While it aids in treatment planning, it does not directly apply therapy or offer a therapeutic effect.
No
The Intended Use section explicitly states, "The physical replicas generated from digital output files are not for diagnostic purpose," and the Device Description focuses on creating 3D representations, measuring, and treatment planning, rather than diagnosing conditions.
Yes
The device description explicitly states that ImmersiveTouch is a "stand-alone modular software package" and lists only software functions. The performance studies focus on software verification and validation, measurements within the software, segmentation within the software, and output file generation, all consistent with a software-only device. While the output can be used for physical replicas, the device itself is the software creating the digital output.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for "transfer of medical imaging information to an output file," "measuring and treatment planning," and generating output for "fabrication of physical replicas." Crucially, it explicitly states that "The physical replicas generated from digital output files are not for diagnostic purpose."
- Device Description: The description focuses on importing, visualizing, segmenting, measuring, and planning on medical images. These are all activities related to image processing and surgical planning, not diagnostic testing performed on biological samples.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, tissue, etc.), detecting specific analytes, or providing diagnostic information based on laboratory tests.
The device is a medical image processing and planning software, which falls under a different regulatory category than IVDs.
N/A
Intended Use / Indications for Use
ImmersiveTouch is intended for use as a software interface and image segmentation system for the transfer of medical imaging information to an output file. ImmersiveTouch is also intended for measuring and treatment planning. ImmersiveTouch output can be used for the fabrication of physical replicas of the output file using traditive manufacturing methods. The physical replicas generated from digital output files are not for diagnostic purpose.
ImmersiveTouch should be used in conjunction with expert clinical judgment.
Product codes (comma separated list FDA assigned to the subject device)
LLZ
Device Description
ImmersiveTouch is a stand-alone modular software package that allows user to import, visualize and segment medical images to create accurate 3D representations. The 3D models can be utilized in ImmersiveTouch for measuring, treatment planning and output file to be further used as an input for additive manufacturing.
This modular package includes, but is not limited to the following functions:
-
- Importing medical images in DICOM format for visualization, segmentation, and analysis.
-
- Viewing of medical imaging data in the axial. coronal and sagittal views.
-
- Calculating a digital 3D model and editing the model.
- Measurements on 3D models. *
-
- Treatment Planning on 3D models with cutting planes and the ability to move cut objects.
-
- File export for 3D Printing.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
medical images in DICOM format
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Software Verification and Validation Testing: Verification against defined requirements, and validation against user needs. Both enduser validation and bench testing were performed. Includes verification of each independent software subsystem against defined requirements, verification of interfaces between software subsystems against defined requirements, and validation of fully integrated systems including all subsystems against overall system requirements.
Measurements Study: Purpose was to evaluate, measure and compare the inter user variability between measurements taken by multiple users in the subject device. Comparison of the inter and intra user measurements showed that all measurements fell within the set acceptance criteria.
Segmentation Study: Purpose was to visually compare segmentation models created by both the subject and predicate devices. The results were validated by subject matter experts. The comparison showed similarity in all models.
Output Study: Purpose was to evaluate, measure and compare the exported models that were created using the subject and predicate device from a CT scan. Comparison between the exported models of both software systems revealed that all measurements fell within the set acceptance criteria.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
ImmersiveTouch, Inc. % P. Pat Banerjee, Ph.D. CEO 910 W. Van Buren St. Suite 715 CHICAGO IL 60607
September 29, 2021
Re: K210726
Trade/Device Name: ImmersiveTouch Regulation Number: 21 CFR 892.2050 Regulation Name: Medical image management and processing system Regulatory Class: Class II Product Code: LLZ Dated: August 20, 2021 Received: August 24, 2021
Dear Dr. Banerjee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmp/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
1
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K210726
Device Name ImmersiveTouch
Indications for Use (Describe)
ImmersiveTouch is intended for use as a software interface and image segmentation system for the transfer of medical imaging information to an output file. ImmersiveTouch is also intended for measuring and treatment planning. ImmersiveTouch output can be used for the fabrication of physical replicas of the output file using traditive manufacturing methods. The physical replicas generated from digital output files are not for diagnostic purpose.
ImmersiveTouch should be used in conjunction with expert clinical judgment.
| Type of Use (Select one or both, as applicable) |
|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the logo for ImmersiveTouch. The logo consists of an orange swirl shape on the left, followed by the text "ImmersiveTouch" in a combination of gray and orange. The "Touch" part of the name is in orange, and there is a registered trademark symbol next to it.
510K Summary K210726
4
Image /page/4/Picture/0 description: The image shows the logo for ImmersiveTouch. The logo consists of an orange swirl with a gray ring around it, followed by the word "Immersive" in gray and "Touch" in orange. There is a registered trademark symbol to the right of the word "Touch".
Contact Person: Dr. P. Pat Banerjee
Date Prepared: September 27th, 2021
Name of Device and Classification Name
Device Name: ImmersiveTouch Regulation Name: Medical image management and processing system Regulation Number: 21 CFR 892.2050 Regulation Class: Class II Product Code: LLZ
Predicate Device
ImmersiveTouch is claimed to be substantially equivalent to Mimics Medical (K183105).
| Device Name: | Mimics Medical |
|---|---|
| Regulation Name: | Picture archiving and communications system |
| Regulation Number: | 21 CFR 892.2050 |
| Regulation Class: | Class II |
| Product Code: | LLZ |
Indications for Use
ImmersiveTouch is intended for use as a software interface and image segmentation system for the transfer of medical imaging information to an output file. ImmersiveTouch is also intended for measuring and treatment planning.
ImmersiveTouch output can be used for the fabrication of physical replicas of the output file using traditional or additive manufacturing methods. The physical replicas generated from digital output files are not for diagnostic purpose.
ImmersiveTouch should be used in conjunction with expert clinical judgment.
5
Image /page/5/Picture/0 description: The image shows the logo for ImmersiveTouch. The logo features a stylized orange arc with a gray arc intersecting it. To the right of the graphic is the company name, with "Immersive" in gray and "Touch" in orange. There is a registered trademark symbol to the right of the word "Touch".
Device Description
ImmersiveTouch is a stand-alone modular software package that allows user to import, visualize and segment medical images to create accurate 3D representations. The 3D models can be utilized in ImmersiveTouch for measuring, treatment planning and output file to be further used as an input for additive manufacturing.
This modular package includes, but is not limited to the following functions:
-
- Importing medical images in DICOM format for visualization, segmentation, and analysis.
-
- Viewing of medical imaging data in the axial. coronal and sagittal views.
-
- Calculating a digital 3D model and editing the model.
- Measurements on 3D models. *
-
- Treatment Planning on 3D models with cutting planes and the ability to move cut objects.
-
- File export for 3D Printing.
Comparison of Technological Characteristics with the Predicate Device
The ImmersiveTouch software employs similar fundamental technologies as the identified predicate devices, including:
-
- The subject and predicate device share similar image segmentation functionalities.
-
- The subject and predicate device both have similar abilities to process, review and analyze medical imaging data
- The subject and predicate device both generate an output file *
The following technological differences exist between the subject and predicate devices:
-
- The inputs to the subject device are equivalent to a subset of the inputs of the predicate device.
-
- The outputs to the subject device are equivalent to a subset of the outputs of the predicate device.
6
Image /page/6/Picture/0 description: The image shows the logo for ImmersiveTouch. The logo consists of an orange swirl and a gray swirl on the left side of the text. The text "ImmersiveTouch" is written in a sans-serif font, with "Immersive" in gray and "Touch" in orange.
Performance Data
Software Verification and Validation Testing
Software verification and validation testing were conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices."
This includes verification against defined requirements, and validation against user needs. Both enduser validation and bench testing were performed.
Software verification and validation includes:
-
- Verification of each independent software subsystem against defined requirements.
-
- Verification of interfaces between software subsystems against defined requirements.
- Validation of fully integrated systems including all subsystems against overall system * requirements.
Measurements Study
The purpose of the study was to evaluate, measure and compare the inter user variability between measurements taken by multiple users in the subject device. Comparison of the inter and intra user measurements showed that all measurements fell within the set acceptance criteria.
Segmentation Study
The purpose of the study was to visually compare segmentation models created by both the subject and predicate devices. The results were validated by subject matter experts. The comparison showed similarity in all models.
Output Study
The purpose of the study was to evaluate, measure and compare the exported models that were created using the subject and predicate device from a CT scan. Comparison between the exported models of both software systems revealed that all measurements fell within the set acceptance criteria.
7
Image /page/7/Picture/0 description: The image shows the logo for ImmersiveTouch. The logo consists of an orange abstract shape on the left, resembling a stylized letter 'A' or a curved arrow, with a gray arc intersecting it. To the right of the shape is the text "ImmersiveTouch", with "Immersive" in gray and "Touch" in orange. A small registered trademark symbol is located to the upper right of the word "Touch".
Summary
The performance data indicates that the verification and validation testing performed on ImmersiveTouch software successfully demonstrates conformity to pre-established specifications and acceptance criteria. The acceptance criteria were established to demonstrate device performance and substantial equivalence of the software to the predicate device.
Conclusions
ImmersiveTouch is substantially equivalent to and is as safe and effective as its predicate device. Both devices incorporate similar inputs, operations, and outputs.